Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

NCT06325683 · clinicaltrials.gov ↗

PHASE2

Phase

SUSPENDED

Status

184

Enrollment

NIH

Sponsor class

Stopped Scheduled Interim Monitoring

Conditions

Progressive Glioblastoma
Recurrent Glioblastoma

Interventions

PROCEDURE: Biopsy Procedure
PROCEDURE: Biospecimen Collection
DRUG: Lomustine
PROCEDURE: Magnetic Resonance Imaging
BIOLOGICAL: Nivolumab
BIOLOGICAL: Relatlimab
PROCEDURE: Surgical Procedure

Sponsor

National Cancer Institute (NCI)